P1150000
Phenylalanine
European Pharmacopoeia (EP) Reference Standard
Synonym(s):
L-Phenylalanine, (S)-2-Amino-3-phenylpropionic acid
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
Linear Formula:
C6H5CH2CH(NH2)CO2H
CAS Number:
Molecular Weight:
165.19
Beilstein/REAXYS Number:
1910408
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
phenylalanine
manufacturer/tradename
EDQM
mp
270-275 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
N[C@@H](Cc1ccccc1)C(O)=O
InChI
1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1
InChI key
COLNVLDHVKWLRT-QMMMGPOBSA-N
Looking for similar products? Visit Product Comparison Guide
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Phenylalanine EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Sohei Nakayama et al.
Cancer research, 74(20), 5891-5902 (2014-08-29)
The discovery of somatic mutations in EGFR and development of EGFR tyrosine kinase inhibitors (TKI) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is available. Here, we show
F J van Spronsen et al.
Journal of inherited metabolic disease, 32(1), 46-51 (2009-02-05)
In phenylketonuria, mental retardation is prevented by a diet that severely restricts natural protein and is supplemented with a phenylalanine-free amino acid mixture. The result is an almost normal outcome, although some neuropsychological disturbances remain. The pathology underlying cognitive dysfunction
Minghua Tang et al.
The American journal of clinical nutrition, 99(4), 891-898 (2014-01-17)
Data on the protein requirements of elderly adults are limited, because it is impractical to conduct repeated nitrogen balance protocols in these vulnerable humans. This study was designed to determine the dietary protein requirement of elderly women by using the
Julia Albrecht et al.
Neuroscience and biobehavioral reviews, 33(3), 414-421 (2008-11-29)
Although pathogenesis of phenylketonuria is not completely understood, a low phenylalanine diet is effective to prevent severe neurological impairment, mental retardation and behavioural difficulties. Treatment recommendations heavily rely on neuropsychological research; however, single study results are ambiguous, what is reflected
John J Mitchell et al.
Genetics in medicine : official journal of the American College of Medical Genetics, 13(8), 697-707 (2011-05-11)
Phenylalanine hydroxylase deficiency is an autosomal recessive disorder that results in intolerance to the dietary intake of the essential amino acid phenylalanine. It occurs in approximately 1:15,000 individuals. Deficiency of this enzyme produces a spectrum of disorders including classic phenylketonuria
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service